As of 2025-09-17, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -16.28. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 3,092.23 mil USD. Apellis's TTM EBITDA according to its financial statements is -189.98 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 11.7x | 9.2x |
| Forward P/E multiples | 10.4x - 16.3x | 12.1x |
| Fair Price | (16.25) - (18.30) | (16.69) |
| Upside | -168.2% - -176.8% | -170.0% |
| Date | EV/EBITDA |
| 2025-09-16 | -16.48 |
| 2025-09-15 | -16.66 |
| 2025-09-12 | -16.96 |
| 2025-09-11 | -17.33 |
| 2025-09-10 | -17.75 |
| 2025-09-09 | -18.28 |
| 2025-09-08 | -18.33 |
| 2025-09-05 | -19.14 |
| 2025-09-04 | -19.49 |
| 2025-09-03 | -18.92 |
| 2025-09-02 | -19.17 |
| 2025-08-29 | -18.77 |
| 2025-08-28 | -19.09 |
| 2025-08-27 | -19.20 |
| 2025-08-26 | -19.01 |
| 2025-08-25 | -18.74 |
| 2025-08-22 | -19.04 |
| 2025-08-21 | -18.80 |
| 2025-08-20 | -18.11 |
| 2025-08-19 | -18.18 |
| 2025-08-18 | -18.62 |
| 2025-08-15 | -18.89 |
| 2025-08-14 | -18.80 |
| 2025-08-13 | -18.11 |
| 2025-08-12 | -16.33 |
| 2025-08-11 | -16.30 |
| 2025-08-08 | -16.64 |
| 2025-08-07 | -16.62 |
| 2025-08-06 | -16.22 |
| 2025-08-05 | -16.53 |
| 2025-08-04 | -16.57 |
| 2025-08-01 | -15.70 |
| 2025-07-31 | -15.29 |
| 2025-07-30 | -13.07 |
| 2025-07-29 | -13.04 |
| 2025-07-28 | -12.91 |
| 2025-07-25 | -13.46 |
| 2025-07-24 | -13.80 |
| 2025-07-23 | -13.67 |
| 2025-07-22 | -13.66 |
| 2025-07-21 | -13.26 |
| 2025-07-18 | -13.39 |
| 2025-07-17 | -13.76 |
| 2025-07-16 | -13.57 |
| 2025-07-15 | -13.31 |
| 2025-07-14 | -13.68 |
| 2025-07-11 | -13.37 |
| 2025-07-10 | -13.43 |
| 2025-07-09 | -13.21 |
| 2025-07-08 | -12.33 |